Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 123.54

+24.8%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	1/12/2010 8:40:27 PM
	Read Replies (1) of 276

Illumina Announces Preliminary Revenue for Fourth Quarter 2009 Company Provides Guidance for 2010 businesswire Related Quotes Symbol Price Change ILMN 39.17 +5.35 Press Release Source: Illumina, Inc. On Tuesday January 12, 2010, 2:48 pm EST SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN - News) today announced revenue for the fourth quarter of 2009 of approximately $176 million based on management’s preliminary review of quarterly financial results. This compares to fourth quarter revenue guidance of a minimum of $165 million and implies fiscal year 2009 revenue of approximately $662 million or annual growth of 15%. It should be noted that this revenue estimate is preliminary and remains subject to audit by our independent registered accounting firm. Today the company also offered the following guidance for fiscal year 2010: Going forward, the company will include non-cash stock compensation charges when it provides non-GAAP earnings per share guidance and discusses its non-GAAP quarterly and annual earnings per share results. The company also will no longer provide quarterly financial guidance. The non-GAAP financial guidance discussed below excludes the incremental interest expense associated with the company’s convertible debt instruments that may be settled in cash, the amortization expense related to intangible assets, the accrual of contingent compensation and in-process research and development related to the Avantome acquisition, and the double dilution associated with the accounting treatment of the company’s outstanding convertible debt and the corresponding call option overlay. We expect revenue growth for the full year 2010 of approximately 20% from anticipated 2009 revenue of $662 million. We expect gross margins in the mid to high 60s and non-GAAP earnings per share between $0.90 and $1.00. We expect the full year pro forma tax rate to be approximately 33%-34% and stock compensation expense of approximately $70 million or a tax adjusted amount of $0.36 per fully diluted pro forma share. We expect full-year weighted-average diluted shares outstanding for the measurement of pro forma amounts to be approximately 132 million.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next